NCT03360630已完成1 期
Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined Anti-PD1 in Advanced NSCLC: A Randomized Controlled Trial
Capital Medical University2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2016年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Progression-free survival of the participants
研究概览
简要总结
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed advanced or metastatic NSCLC.
- •Patients must have received previously standard therapy for that malignancy or declined to chemotherapy/radiotherapy.
- •Estimated life expectancy > 3 months.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or
- •Age 18 to
- •Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR <1.5 (unless patient is receiving warfarin in which case PT-INR must be <3), PTT <1.5X ULN
- •Adequate renal and hepatic function, with serum creatinine < 1.5 mg/ dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.
排除标准
- •Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.
- •Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
- •Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
- •Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated.
- •Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
- •Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.
- •Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
- •Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
结局指标
主要结局
Progression-free survival of the participants
时间窗: 12 months
From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first.
次要结局
- Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE)(24 months)
- Overall survival of the participants(OS)(24 months)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(24 months)
- Molecular Tumor Burden Index(24 months)
研究者
Jun Ren MD, PhD
Director, Comprehensive Cancer Center
Capital Medical University
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of S-1 Plus DC-CIK for Patients With Advanced Gastric CancerGastric CancerNCT01783951Capital Medical University63
Unknown
2 期
A Study of DC-CIK to Treat Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)NCT01821482Guangxi Medical University100
已完成
1 期
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic CancerPancreatic CancerNCT01781520Capital Medical University47
Unknown
2 期
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of TreatmentGastric CancerNCT02504229Beijing Biohealthcare Biotechnology Co.,Ltd80
Unknown
1 期
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular CarcinomaRecurrence Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT02638857Second Military Medical University60